Search results for " psychotic disorder"

showing 8 items of 8 documents

Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study

2021

AbstractBackgroundPerceived discrimination is associated with worse mental health. Few studies have assessed whether perceived discrimination (i) is associated with the risk of psychotic disorders and (ii) contributes to an increased risk among minority ethnic groups relative to the ethnic majority.MethodsWe used data from the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2, a population-based case−control study of incident psychotic disorders in 17 catchment sites across six countries. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) for the associations between perceived discrimination and psychosis using mixed-…

Mediation (statistics)LIFE EVENTSMIGRATIONPopulationEthnic groupLogistic regressionpsychosiOdds03 medical and health sciences0302 clinical medicineMINORIAS ÉTNICASSCHIZOPHRENIAMedicinepsychosisfirst-episodeeducationCase−controlApplied PsychologyTRAUMACase-control discrimination first-episode minority ethnic group multi-country psychosis psychotic disorderFirst episodemulti-countryeducation.field_of_studyminority ethnic groupCONSEQUENCESbusiness.industryAbsolute risk reductionPATHWAYSOdds ratiopsychotic disorderCase-controlMEDIATION ANALYSIS030227 psychiatryPsychiatry and Mental health[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]HEALTHbusinessCHILDHOOD ADVERSITIES030217 neurology & neurosurgeryDemographydiscrimination
researchProduct

The influence of risk factors on the onset and outcome of psychosis: What we learned from the GAP study

2020

The GAP multidisciplinary study carried out in South London, recruited 410 first episode of psychosis patients and 370 controls; the aim was to elucidate the multiple genetic and environmental factors influencing the onset and outcome of psychosis. The study demonstrated the risk increasing effect of adversity in childhood (especially parental loss, abuse, and bullying) on onset of psychosis especially positive symptoms. Adverse life events more proximal to onset, being from an ethnic minority, and cannabis use also played important roles; indeed, one quarter of new cases of psychosis could be attributed to use of high potency cannabis. The “jumping to conclusions” bias appeared to mediate …

PsychosisHypothalamo-Hypophyseal SystemVulnerabilityMultidisciplinary studyEthnic groupPituitary-Adrenal SystemPsychosi03 medical and health sciences0302 clinical medicineRisk FactorsLondonmedicineEthnicityHumansFirst episodeChildBiological PsychiatryMinority GroupsOutcomeFirst episodeMarkersFirst episode; Markers; Outcome; Psychosis; Schizophreniabiologybusiness.industryMarkermedicine.diseasebiology.organism_classificationPsychosis030227 psychiatryFirst episode; Markers; Outcome; Psychosis; Schizophrenia; Child; Ethnicity; Humans; London; Minority Groups; Pituitary-Adrenal System; Risk Factors; Hypothalamo-Hypophyseal System; Psychotic DisordersPsychiatry and Mental healthIncreased riskPsychotic DisordersJumping to conclusionsSchizophreniaCannabisbusiness030217 neurology & neurosurgeryClinical psychology
researchProduct

Substance use, medication adherence and outcome one year following a first episode of psychosis

2016

Both substance use and poor medication adherence are associated with poor outcome in psychosis. To clarify the contributions of substance use and poor medication adherence to poor outcome in the year following a first episode of psychosis, 205 patients were evaluated for use of tobacco, alcohol, cannabis and stimulants at their psychosis onset, and in a 1-year follow-up. Data on medication adherence and symptom remission were also collected. Patients had high rates of overall substance use before (37-65%) and after psychosis onset (45-66%). 44% showed poor medication adherence and 55% did not reach remission from psychosis. Nicotine dependence and cannabis use after psychosis onset signific…

Nicotine dependenceAdultMalePsychosismedicine.medical_specialtyFirst episode psychosisRemissionSubstance-Related DisordersMedication adherenceSubstance useCannabis useMedication AdherenceCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease03 medical and health sciencesYoung Adult0302 clinical medicineSettore M-PSI/08 - Psicologia ClinicamedicineHumansYoung adultCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Psychotic Disorders; Substance-Related Disorders; Treatment Outcome; Young AdultNicotine dependencePsychiatryMedication adherenceSettore MED/25 - PsichiatriaBiological PsychiatryFirst episodebiologyCannabis useMiddle Agedmedicine.diseasebiology.organism_classificationFirst episode psychosi030227 psychiatryTreatment OutcomePsychotic DisordersPsychiatry and Mental HealthAcute DiseaseFemaleCannabisSubstance usePsychology030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed into the Developmental Risk Factor Model of Psychosis

2017

At its re-birth 30 years ago, the neurodevelopment hypothesis of schizophrenia focussed on aberrant genes and early neural hazards, but then it grew to include ideas concerning aberrant synaptic pruning in adolescence. The hypothesis had its own stormy development and it endured some difficult teenage years when a resurgence of interest in neurodegeneration threatened its survival. In early adult life, it over-reached itself with some reductionists claiming that schizophrenia was simply a neurodevelopmental disease. However, by age 30, the hypothesis has matured sufficiently to incorporated childhood and adult adversity, urban living and migration, as well as heavy cannabis use, as importan…

Striatal dopaminePsychosismedicine.medical_specialtyDopamineSynaptic pruningDiseaseHistory 21st CenturyRisk factor model03 medical and health sciences0302 clinical medicinesociodevelopmentmedicineHumansrisk factorsPsychiatryUrban livingPsychiatryneurodevelopmentdopamine neurodevelopment risk factors sociodevelopment Dopamine History 20th Century History 21st Century Humans Psychiatry Psychotic Disorders SchizophreniaHistory 20th Centurymedicine.disease030227 psychiatryPsychiatry and Mental healthAdult lifemedicine.anatomical_structurePsychotic DisordersSchizophreniaSchizophreniadopaminePsychology030217 neurology & neurosurgeryRegular ArticlesClinical psychology
researchProduct

Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

2013

UNLABELLED: Cannabis use is associated with an earlier age of onset of psychosis (AOP). However, the reasons for this remain debated. METHODS: We applied a Cox proportional hazards model to 410 first-episode psychosis patients to investigate the association between gender, patterns of cannabis use, and AOP. RESULTS: Patients with a history of cannabis use presented with their first episode of psychosis at a younger age (mean years = 28.2, SD = 8.0; median years = 27.1) than those who never used cannabis (mean years = 31.4, SD = 9.9; median years = 30.0; hazard ratio [HR] = 1.42; 95% CI: 1.16-1.74; P < .001). This association remained significant after controlling for gender (HR = 1.39; 95% …

AdultAffective Disorders PsychoticMaleRiskage of onset cannabis drug use gender high-potency cannabis psychotic disorders survival plotsPsychosisPediatricsmedicine.medical_specialtySex FactorsDelta-9-tetrahydrocannabinolSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.medicineHumansAge of OnsetPsychiatrySettore MED/25 - PsichiatriaCannabisFirst episodebiologyProportional hazards modelHazard ratioRegular Articlemedicine.diseasebiology.organism_classificationPsychiatry and Mental healthPsychotic DisordersSchizophreniaFemaleCannabisAge of onsetPsychologySchizophrenia bulletin
researchProduct

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: Results from the EU-GEI case-control study

2021

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme. The Brazilian study was funded by grant 2012-0417-0 from the São Paulo Research Foundation. Dr Jongsma is funded by the Economic and Social Research Council (grant ES/S011714/1). Dr Kirkbride is funded by the Wellcome Trust and Royal Society (Grant 101272/Z/13/Z). Dr Jongsma and Professor Jones are funded by the National Institute of Health Research Collaboration of Leadership in Applied Health Research and Care East of England. Professor Rutten is funded…

MaleSocial Determinants of HealthEthnic groupPoison controlIMMIGRANTSOccupational safety and health0302 clinical medicinepsychotic disordersSCHIZOPHRENIADiscriminationOdds RatioApplied PsychologyRISKHYPOTHESISCommunication BarriersLinguistic distanceMiddle AgedDiscrimination; epidemiology; ethnicity; psychotic disorders; social disadvantage3. Good healthSocial researchEuropePsychiatry and Mental healthMIGRANT GROUPSethnicityFemaleepidemiologySTRIATAL DOPAMINE FUNCTIONAdultAdolescentDISORDERSsocial disadvantage1ST EPISODEBlack PeopleLibrary scienceTRANSTORNOS PSICÓTICOSWhite PeopleYoung Adult03 medical and health sciencesFirst episode psychosisPolitical scienceHumansMinority statusINCIDENCE RATESHealth Status DisparitiesOriginal Articlespsychotic disorder030227 psychiatryCase-Control StudiesEthnic and Racial MinoritiesIDENTITYGene-Environment InteractionSocial disadvantage030217 neurology & neurosurgery
researchProduct

Differences in cannabis-related experiences between patients with a first episode of psychosis and controls

2016

BackgroundMany studies have reported that cannabis use increases the risk of a first episode of psychosis (FEP). However, only a few studies have investigated the nature of cannabis-related experiences in FEP patients, and none has examined whether these experiences are similar in FEP and general populations. The aim of this study was to explore differences in self-reported cannabis experiences between FEP and non-psychotic populations.MethodA total of 252 subjects, who met International Classification of Diseases (ICD)-10 criteria for FEP, and 217 controls who reported cannabis use were selected from the Genetics and Psychosis (GAP) study. The Medical Research Council Social Schedule and t…

AdultMalePsychosismedicine.medical_specialtyExacerbationPopulationMarijuana SmokingSociodemographic datapsychosiPsychotic Disorder03 medical and health sciencesYoung Adult0302 clinical medicineexperienceSurveys and QuestionnairesmedicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.HumansSurveys and QuestionnaireCannabiYoung adulteducationPsychiatrySettore MED/25 - PsichiatriaApplied PsychologyCannabisCannabis; Cannabis Experience Questionnaire; experiences; first episode of psychosis; psychosis; Adult; Cannabis; Female; Humans; Linear Models; Male; Marijuana Smoking; Psychiatric Status Rating Scales; Psychotic Disorders; Surveys and Questionnaires; Young Adult; Applied Psychology; Psychiatry and Mental Healthfirst episode of psychosiFirst episodePsychiatric Status Rating Scaleseducation.field_of_studybiologyCannabis usePsychiatric Status Rating Scalemedicine.diseasebiology.organism_classification030227 psychiatryPsychotic DisordersPsychiatry and Mental HealthCannabis Experience QuestionnaireLinear ModelsLinear ModelFemaleCannabisPsychology030217 neurology & neurosurgeryClinical psychologyHuman
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct